Cited 26 times in
In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 용동은 | - |
dc.contributor.author | 이경원 | - |
dc.contributor.author | 이혁민 | - |
dc.contributor.author | 정석훈 | - |
dc.contributor.author | 홍덕진 | - |
dc.date.accessioned | 2017-10-26T07:33:06Z | - |
dc.date.available | 2017-10-26T07:33:06Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0732-8893 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/152181 | - |
dc.description.abstract | Increased use of colistin in a clinical setting had resulted in the emergence of colistin-resistant (CoR) Acinetobacter baumannii. Combination therapy has been studied as a new approach to treat infections caused by A. baumannii. Here, we investigated the in vitro antimicrobial synergistic activities of several antimicrobial agent combinations against CoR A. baumannii. A total of 41 non-duplicate clinical isolates of CoR A. baumannii from a tertiary care hospital in Korea were prospectively collected from April 2012 to December 2014. As a control group, 41 carbapenem-resistant but colistin-susceptible (CoS) A. baumannii strains were also evaluated. Minimum inhibitory concentrations (MICs) of antimicrobial agents were determined by Etest in triplicate, and in vitro synergy tests were performed by the Etest MIC:MIC ratio method. Synergistic activity was determined as the sum of each antimicrobial agent's fractional inhibitory concentration evaluated (ΣFIC): synergy, ≤0.5; indifference, >0.5-4; and antagonism, >4. Synergistic activities were more frequently observed in the CoR group than the CoS group for combinations of colistin-rifampicin (80.5% vs. 14.6%, P< 0.0001), colistin-meropenem (85.4% vs. 4.9%, P< 0.0001), and colistin-imipenem (46.3% vs. 2.4%, P< 0.0001). Combination with rifampicin or meropenem lowered colistin MICs against CoR A. baumannii clinical isolates to the susceptible range (≤ 2 μg/mL) more frequently (61.0%, 25/41, both) than combination with imipenem (29.3%, 12/41). Clinical trials are needed to prove the in vivo efficacy of those antimicrobial combinations that exhibited significant in vitro antimicrobial synergistic effects against CoR A. baumannii. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier Biomedical | - |
dc.relation.isPartOf | DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Acinetobacter Infections/microbiology* | - |
dc.subject.MESH | Acinetobacter baumannii/drug effects* | - |
dc.subject.MESH | Acinetobacter baumannii/isolation & purification | - |
dc.subject.MESH | Anti-Bacterial Agents/pharmacology* | - |
dc.subject.MESH | Carbapenems/pharmacology* | - |
dc.subject.MESH | Colistin/pharmacology* | - |
dc.subject.MESH | Drug Resistance, Bacterial | - |
dc.subject.MESH | Drug Synergism* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Microbial Sensitivity Tests | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Rifampin/pharmacology* | - |
dc.subject.MESH | Tertiary Care Centers | - |
dc.title | In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates | - |
dc.type | Article | - |
dc.publisher.location | United States | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Laboratory Medicine | - |
dc.contributor.googleauthor | Duck Jin Hong | - |
dc.contributor.googleauthor | Jung Ok Kim | - |
dc.contributor.googleauthor | Hyukmin Lee | - |
dc.contributor.googleauthor | Eun-Jeong Yoon | - |
dc.contributor.googleauthor | SeokHoon Jeong | - |
dc.contributor.googleauthor | Dongeun Yong | - |
dc.contributor.googleauthor | Kyungwon Lee | - |
dc.identifier.doi | 10.1016/j.diagmicrobio.2016.07.017 | - |
dc.contributor.localId | A02649 | - |
dc.contributor.localId | A03286 | - |
dc.contributor.localId | A03619 | - |
dc.contributor.localId | A04389 | - |
dc.contributor.localId | A02423 | - |
dc.relation.journalcode | J00731 | - |
dc.identifier.eissn | 1879-0070 | - |
dc.identifier.pmid | 27475960 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0732889316302115?via%3Dihub | - |
dc.subject.keyword | Acinetobacter baumannnii | - |
dc.subject.keyword | Colistin | - |
dc.subject.keyword | Combination | - |
dc.subject.keyword | Meropenem | - |
dc.subject.keyword | Rifampicin | - |
dc.subject.keyword | Synergism | - |
dc.contributor.alternativeName | Yong, Dong Eun | - |
dc.contributor.alternativeName | Lee, Kyung Won | - |
dc.contributor.alternativeName | Lee, Hyuk Min | - |
dc.contributor.alternativeName | Jeong, Seok Hoon | - |
dc.contributor.alternativeName | Hong, Duck Jin | - |
dc.contributor.affiliatedAuthor | Lee, Kyung Won | - |
dc.contributor.affiliatedAuthor | Lee, Hyuk Min | - |
dc.contributor.affiliatedAuthor | Jeong, Seok Hoon | - |
dc.contributor.affiliatedAuthor | Hong, Duck Jin | - |
dc.contributor.affiliatedAuthor | Yong, Dong Eun | - |
dc.citation.volume | 86 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 184 | - |
dc.citation.endPage | 189 | - |
dc.identifier.bibliographicCitation | DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, Vol.86(2) : 184-189, 2016 | - |
dc.date.modified | 2017-10-24 | - |
dc.identifier.rimsid | 46959 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.